Methylphenidate
متیلفنیدیت
🧠 Nervous SystemCNS stimulant
Market / country: 🇺🇸 USA
Ritalin (US)
🧮 Dose calculator
Attention-deficit/hyperactivity disorder · Regimen source: FDA Ritalin · 2.2FDA Ritalin · 8.4
- • Before breakfast and lunch; increase 5–10 mg weekly; above 60 mg/day not recommended. Discontinue if no improvement after one month. FDA Ritalin · 2.2FDA Ritalin · 2.3
- • Before starting: screen for cardiac disease, family history of sudden death, tics/Tourette's. FDA Ritalin · 2.1
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ MAOI within 14 days (hypertensive crisis); hypersensitivity. FDA Ritalin · 4
- ⛔ Not established under 6 years. FDA Ritalin · 8.4
Warnings
- • Boxed warning: high potential for abuse, misuse and addiction; risk of overdose and death. FDA Ritalin · WARNING: ABUSE, MISUSE, AND ADDICTION
Monitoring
- • Monitor growth (height and weight) during treatment. FDA Ritalin · 8.4
Formulations
- 5 mg tablet — tablet 🇺🇸 USA FDA Ritalin · 3
- 10 mg tablet (partial bisection) — tablet 🇺🇸 USA FDA Ritalin · 3
- 20 mg tablet (partial bisection) — tablet 🇺🇸 USA FDA Ritalin · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Ritalin · 8.1
“Risk Summary Published studies and postmarketing reports on methylphenidate use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Ritalin · 8.2
“Risk Summary Limited published literature, based on milk sampling from seven mothers, reports that methylphenidate is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Ritalin · 8.4
“The safety and effectiveness of Ritalin for the treatment of ADHD have been established in pediatric patients aged 6 to 17 years.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Ritalin · 8.5
“Ritalin has not been studied in the geriatric population.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA010187
- DailyMed (FDA label)FDA Ritalin
- MedlinePlus (NIH)MethylphenidateMethylphenidate Transdermal Patch
- WHO ATC/DDDN06BA04
- Darooyab (Iran)Methylphenidate
🇮🇷 Registered in Iran Darooyab · G-3392/Methylphenidate
Dosage forms with Iranian generic codes, per Darooyab.
- 01328 · METHYLPHENIDATE HCL 10MG TAB · قرص متیلفنیدات هیدروکلراید ۱۰ میلیگرم
- 07991 · METHYLPHENIDATE HCL 20MG SR TAB · قرص آهستهرهش متیلفنیدات هیدروکلراید ۲۰ میلیگرم
- 50684 · METHYLPHENIDATE HCL TABLET, EXTENDED RELEASE ORAL 18 mg · قرص آهستهرهش متیلفنیدات هیدروکلراید ۱۸ میلیگرم
- 50685 · METHYLPHENIDATE HCL TABLET, EXTENDED RELEASE ORAL 36 mg · قرص آهستهرهش متیلفنیدات هیدروکلراید ۳۶ میلیگرم
- 50686 · METHYLPHENIDATE HCL TABLET, EXTENDED RELEASE ORAL 54 mg · قرص آهستهرهش متیلفنیدات هیدروکلراید ۵۴ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Ritalin · 3FDA Ritalin · 2.2FDA Ritalin · 8.4FDA Ritalin · 2.3FDA Ritalin · 2.1FDA Ritalin · 4FDA Ritalin · WARNING: ABUSE, MISUSE, AND ADDICTIONFDA Ritalin · 8.1FDA Ritalin · 8.2FDA Ritalin · 8.5FDA Ritalin · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-3392/Methylphenidate
- Clinical review⚠ Unverified